Antipsychotic drug-induced weight gain: development of an animal model
Open Access
- 29 March 2005
- journal article
- research article
- Published by Springer Nature in International Journal of Obesity
- Vol. 29 (6) , 607-614
Abstract
OBJECTIVE: Weight gain is a prominent effect of most atypical antipsychotic drugs (AAPDs); yet, the mechanisms are not fully understood and no well-established mouse models exist for investigating the mechanisms. Thus, we developed a mouse model to evaluate the effects of AAPDs on eating, body weight (BW), and body composition. METHODS: Female C57BL/6J mice were used to test olanzapine, quetiapine, ziprasidone, and risperidone. Mice were acclimated to individual housing, given ad libitum access to chow and water, dosed with placebo peanut butter pills for 1 week, and then dosed daily with AAPD-laced peanut butter pills for 4 weeks. Weekly food intakes and BWs were measured, and body compositions were determined at the end of each experiment. RESULTS: After 4 weeks of treatment, olanzapine, quetiapine, ziprasidone, and risperidone caused significant weight increases, but only olanzapine and quetiapine were associated with significantly increased food intake. Body composition data revealed that olanzapine-treated mice had more relative fat mass and risperidone-treated mice had more relative lean mass than did control mice. Quetiapine and ziprasidone did not significantly affect relative body composition even though BW was increased. CONCLUSIONS: Oral AAPD administration causes increased BW in female mice. Our mouse model of AAPD-induced weight gain resembles the human response to these medications and will be used to investigate the mechanisms for weight gain and fat accumulation.Keywords
This publication has 31 references indexed in Scilit:
- Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in humanPharmacology Biochemistry and Behavior, 2003
- Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With OlanzapineAmerican Journal of Psychiatry, 2002
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Association of Olanzapine-Induced Weight Gain With an Increase in Body FatAmerican Journal of Psychiatry, 2001
- Bodyweight Gain Associated with Atypical AntipsychoticsCNS Drugs, 2001
- The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophreniaClinical Therapeutics, 2000
- Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic DisorderJournal of Child and Adolescent Psychopharmacology, 1999
- Systemic sulpiride increases dopamine metabolites in the lateral hypothalamusPharmacology Biochemistry and Behavior, 1990
- Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?Pharmacology Biochemistry and Behavior, 1987
- The effect of apparatus, extraction time, and solvent type on lipid extractions of snow geeseCanadian Journal of Zoology, 1985